Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Timothy Sloan

Physician Assistant, Medical Okemos, MI Physician Assistant

NPI 1265623425 CMS profile 11125506

3413 Woods Edge Drive, Okemos, MI 48864

Open in the dashboard

General payments

$8,704

439 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Sloan of Okemos, MI is reported in the CMS Open Payments database as having received $8,704 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,961 80
2024 General $2,027 97
2023 General $1,238 70
2022 General $1,970 105
2021 General $1,509 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Sloan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Timothy Sloan were reported at $1,961. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Timothy Sloan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,509 $156 $41–$563 $132
2022 $1,970 $185 $55–$649 $149
2023 $1,238 $199 $58–$717 $160
2024 $2,027 $206 $62–$740 $164
2025 $1,961 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $1,147 64 payments
  2. Novartis Pharmaceuticals Corporation $1,015 79 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $879 30 payments
  4. Merck Sharp & Dohme Corporation $846 45 payments
  5. AstraZeneca Pharmaceuticals LP $563 21 payments
  6. Amgen Inc. $482 26 payments
  7. E.R. Squibb & Sons, L.L.C. $396 29 payments
  8. Boston Scientific Corporation $320 11 payments
  9. Pfizer Inc. $290 16 payments
  10. Scpharmaceuticals Inc. $287 12 payments
  11. Other $2,478 106 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,492 433 payments
  2. Education $213 6 payments
Products named General payments · program years 2021–2025
  1. Kerendia $1,147 64 payments
  2. VERQUVO $1,045 53 payments
  3. LEQVIO $596 47 payments
  4. Repatha $482 26 payments
  5. JARDIANCE Diabetes $473 17 payments
  6. FARXIGA $436 12 payments
  7. JARDIANCE Diabetes $407 13 payments
  8. BRILINTA $310 11 payments
  9. FUROSCIX $287 12 payments
  10. ELIQUIS $268 20 payments
  11. Other $4,109 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,144

Median for Physician Assistant: 241

Drug cost

$472,484

Median for Physician Assistant: $4,110

Branded share of claims

28.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 114 $151,754
Entresto Sacubitril/Valsartan Brand 81 $117,344
Xarelto Rivaroxaban Brand 64 $75,294
Jardiance Empagliflozin Brand 22 $27,699
Multaq Dronedarone Hcl Brand 14 $26,585
Repatha Sureclick Evolocumab Brand 16 $24,614
Kerendia Finerenone Brand 14 $9,076
Ranolazine Er Ranolazine Brand 42 $5,380
Metoprolol Succinate Generic 202 $3,604
Prasugrel Hcl Generic 42 $3,278

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $336
$336 22 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $264
$264 14 —
VERQUVO
  • Merck Sharp & Dohme Corporation $199
$199 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $162
$162 — —
Repatha
  • Amgen Inc. $118
$118 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record